Genomic Vision EBIT per Share
The EBIT per Share of Genomic Vision (GV.PA) as of Sep 8, 2026 is -0.09 EUR. In the previous year, EBIT per Share was -0.10 EUR — a change of -10.87% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.09EUR
YoY
-10.87%
Last updated:
EBIT per Share of Genomic Vision is 2026 -0.09 EUR. EBIT per Share of Genomic Vision was 2025 -0.10 EUR. It decreases by -10.87% higher compared to the previous year.
The Genomic Vision EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2015
-0.99 EUR
Jan 1, 2016
-1.94 EUR
Jan 1, 2017
-1.71 EUR
Jan 1, 2018
-0.75 EUR
Jan 1, 2019
-0.16 EUR
Jan 1, 2020
-0.12 EUR
Jan 1, 2021
-0.10 EUR
Jan 1, 2022
-0.09 EUR
| YEAR | EBIT per Share | YoY |
|---|---|---|
| -0.09EUR | -10.87% | |
| -0.10EUR | -17.80% | |
| -0.12EUR | -27.81% | |
| -0.16EUR | -78.24% | |
| -0.75EUR | -56.00% | |
| -1.71EUR | -11.76% | |
| -1.94EUR | +97.11% | |
| -0.99EUR | +78.20% | |
| -0.55EUR | +25.20% | |
| -0.44EUR | -44.25% | |
| -0.79EUR | +92.78% | |
| -0.41EUR | — |
Access this data via the Eulerpool API
Genomic Vision Stock analysis
What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Genomic Vision stock
EBIT per Share of Genomic Vision is -0.09 EUR in 2026.
EBIT per Share of Genomic Vision changed from -0.10 EUR to -0.09 EUR, representing a -10.87% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Genomic Vision since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Genomic Vision
All Key Metrics — Genomic Vision
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth